Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis

被引:125
作者
Hu, Kaimin [1 ]
Lou, Lixia [2 ]
Ye, Juan [2 ]
Zhang, Suzhan [1 ]
机构
[1] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Inst Canc, Hangzhou 310003, Zhejiang, Peoples R China
[2] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Ophthalmol, Hangzhou 310003, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
PRETREATMENT NEUTROPHIL; HEPATOCELLULAR-CARCINOMA; PUBLICATION BIAS; EUROPEAN COHORT; CANCER; SURVIVAL; INFLAMMATION; NEPHRECTOMY; METASTASIS; STATISTICS;
D O I
10.1136/bmjopen-2014-006404
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Increasing evidence suggests that cancer-associated inflammation is associated with poor prognosis in patients with cancer. The role of the neutrophil-lymphocyte ratio (NLR) as a predictor in renal cell carcinoma (RCC) remains controversial. We conducted the meta-analysis to determine the association between NLR and clinical outcome of patients with RCC. Methods and materials: Studies were identified from PubMed and EMBASE databases in March 2014. Meta-analysis was performed to generate combined HRs with 95% CIs for overall survival (OS) and recurrence-free/progress-free survival (RFS/PFS). Results: 15 cohorts containing 3357 patients were included. Our analysis results indicated that elevated NLR predicted poorer OS (HR=1.82, 95% CI 1.51 to 2.19) and RFS/PFS (HR=2.18, 95% CI 1.75 to 2.71) in patients with RCC. These findings were robust when stratified by study region, sample size, therapeutic intervention, types of RCC and study quality. However, it differed significantly by assessment of the cut-off value defining 'elevated NLR' in RFS/PFS (p=0.004). The heterogeneity in our meta-analysis was mild to moderate. Conclusions: Elevated NLR indicates a poorer prognosis for patients with RCC. NLR should be monitored in patients with RCC for rational risk stratification and treatment individualisation.
引用
收藏
页数:11
相关论文
共 42 条
[1]   Statistics Notes - Interaction revisited: the difference between two estimates [J].
Altman, DG ;
Bland, JM .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7382) :219-219
[2]  
[Anonymous], 2007, J SUPPORT ONCOL
[3]  
[Anonymous], 2007, J SUPPORT ONCOL
[4]  
[Anonymous], J CLIN ONCOL
[5]   OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].
BEGG, CB ;
MAZUMDAR, M .
BIOMETRICS, 1994, 50 (04) :1088-1101
[6]   Is the Pretreatment Neutrophil to Lymphocyte Ratio an Important Prognostic Parameter in Patients with Metastatic Renal Cell Carcinoma? [J].
Cetin, Bulent ;
Berk, Veli ;
Kaplan, Mehmet Ali ;
Afsar, Baris ;
Tufan, Gulnihal ;
Ozkan, Metin ;
Isikdogan, Abdurahman ;
Benekli, Mustafa ;
Coskun, Ugur ;
Buyukberber, Suleyman .
CLINICAL GENITOURINARY CANCER, 2013, 11 (02) :141-148
[7]   Epidemiology and risk factors for kidney cancer [J].
Chow, Wong-Ho ;
Dong, Linda M. ;
Devesa, Susan S. .
NATURE REVIEWS UROLOGY, 2010, 7 (05) :245-257
[8]   Prognostic Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Localized Nonclear Cell Renal Cell Carcinoma [J].
de Martino, Michela ;
Pantuck, Allan J. ;
Hofbauer, Sebastian ;
Waldert, Matthias ;
Shariat, Shahrokh F. ;
Belldegrun, Arie S. ;
Klatte, Tobias .
JOURNAL OF UROLOGY, 2013, 190 (06) :1999-2004
[9]   The Protease Activated Receptor 1 Gene Variation IVSn-14 A > T is Associated with Distant Metastasis and Cancer Specific Survival in Renal Cell Carcinoma [J].
de Martino, Michela ;
Haitel, Andrea ;
Schatzl, Georg ;
Klatte, Tobias .
JOURNAL OF UROLOGY, 2013, 190 (04) :1392-1397
[10]   Random-effects model for meta-analysis of clinical trials: An update [J].
DerSimonian, Rebecca ;
Kacker, Raghu .
CONTEMPORARY CLINICAL TRIALS, 2007, 28 (02) :105-114